We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
189 result(s) found, displaying 31 to 40
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALTZ ixekizumab 80 mg/mL solution for injection prefilled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALTZ ixekizumab 80 mg/mL solution for injection prefilled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 25 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 12.5 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 8.33 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 20.83 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 4.17 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 16.67 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EBGLYSS lebrikizumab 250 mg/2 mL solution for injection autoinjector (pre-filled pen).
-
Australian public assessment report (AusPar)Ebglyss (lebrikizumab) was approved to treat severe atopic dermatitis in adult and adolescent patients.